Scholarlink

<p>Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy characterized by an immunosuppressive tumor environment. Neutrophil extracellular traps (NETs) have gained recognition in playing a critical role in cancer progression and formulation of the PDAC TME, making them a target for novel PDAC therapies. Herein, we utilize a <i>Lactococcus</i> strain expressing group A streptococcal collagen-like protein 1 (Scl1) to stimulate anti-tumor immunity and inhibit cancer promoting NETs. Orthotopically implanted male and female C57BL6/J or NET-deficient PAD4−/− mice were intra-tumorally or intra-peritoneally injected with <i>Lactococcus</i> wild-type lacking Scl1, Scl1-producing <i>Lactococcus</i>::620, or PBS control. Sera were collected to assess circulating NET markers. A decreased tumor burden, as well as infiltration of anti-tumor CD8 + T and dendritic cells was observed in mice treated with Scl1-expressing <i>Lactococcus</i>::620 compared to <i>Lactococcus</i> wild-type and PBS control. Mice treated with <i>Lactococcus</i>::620 showed reduced cell-free DNA in their sera as a marker for decreased NETosis. These effects were abrogated in PAD4−/− mice, suggesting a NET-dependent anti-tumor effect by Scl1. This study demonstrates a novel therapeutic concept against PDAC using an engineered Scl1-expressing <i>Lactococcus</i> strain. Our results advocate for Scl1-based cancer therapy as an immunomodulator of the PDAC tumor microenvironment. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application of group A streptococcal collagen-like protein 1-expressing Lactococcus as a novel immunotherapeutic against pancreatic ductal adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Emily A. Godfrey,
  • Soo Jeon Choi,
  • Michael Sestito,
  • Tracy W. Liu,
  • Slawomir Lukomski,
  • Brian A. Boone

摘要

Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy characterized by an immunosuppressive tumor environment. Neutrophil extracellular traps (NETs) have gained recognition in playing a critical role in cancer progression and formulation of the PDAC TME, making them a target for novel PDAC therapies. Herein, we utilize a Lactococcus strain expressing group A streptococcal collagen-like protein 1 (Scl1) to stimulate anti-tumor immunity and inhibit cancer promoting NETs. Orthotopically implanted male and female C57BL6/J or NET-deficient PAD4−/− mice were intra-tumorally or intra-peritoneally injected with Lactococcus wild-type lacking Scl1, Scl1-producing Lactococcus::620, or PBS control. Sera were collected to assess circulating NET markers. A decreased tumor burden, as well as infiltration of anti-tumor CD8 + T and dendritic cells was observed in mice treated with Scl1-expressing Lactococcus::620 compared to Lactococcus wild-type and PBS control. Mice treated with Lactococcus::620 showed reduced cell-free DNA in their sera as a marker for decreased NETosis. These effects were abrogated in PAD4−/− mice, suggesting a NET-dependent anti-tumor effect by Scl1. This study demonstrates a novel therapeutic concept against PDAC using an engineered Scl1-expressing Lactococcus strain. Our results advocate for Scl1-based cancer therapy as an immunomodulator of the PDAC tumor microenvironment.